Osteopontin has a crucial role in osteoclast-like multinucleated giant cell formation

Journal of Cellular Biochemistry

Volumn 115, Issue 3, 2014, Pages 585-595

  Oh, Yukiko ^a   Oh, Iekuni ^a   Morimoto, Junko ^b   Uede, Toshimitsu ^b   Morimoto, Akira ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

IMMATURE DENDRITIC CELL; INFLAMMATORY BONE DISEASE; MULTINUCLEATED GIANT CELL; OSTEOCLAST; OSTEOPONTIN

Indexed keywords

ALPHA9BETA1 INTEGRIN; ARGININE; ASPARTIC ACID; CASPASE 3; CD44V6 ANTIGEN; GLYCINE; INTEGRIN; OSTEOPONTIN; PROTEINASE; REACTIVE OXYGEN METABOLITE; SVVGLR PEPTIDE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CELL VIABILITY; DENDRITIC CELL; DOWN REGULATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GIANT CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MONOCYTE; NORMAL HUMAN; OSTEOCLAST; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

IMMATURE DENDRITIC CELL; INFLAMMATORY BONE DISEASE; MULTINUCLEATED GIANT CELL; OSTEOCLAST; OSTEOPONTIN;

ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; DENDRITIC CELLS; GIANT CELLS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; OLIGOPEPTIDES; OSTEOCLASTS; OSTEOPONTIN; RNA, SMALL INTERFERING;

EID: 84892748554     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24695     Document Type: Article

References (34)

1. Abe K, Yoshimura Y, Deyama Y, Kikuiri T, Hasegawa T, Tei K, Shinoda H, Suzuki K, Kitagawa Y,. 2012. Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells. Int J Mol Med 29: 1007-1015.
2. Allen CE, Li L, Peters TL, Leung HC, Yu A, Man TK, Gurusiddappa S, Phillips MT, Hicks MJ, Gaikwad A, Merad M, McClain KL,. 2010. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 184: 4557-4567.
3. Aruoma OI, Halliwell B, Hoey BM, Butler J,. 1989. The antioxidant action of N-acetylcysteine: Its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6: 593-597.
4. Chapuis F, Rosenzwajg M, Yagello M, Ekman M, Biberfeld P, Gluckman JC,. 1997. Differentiation of human dendritic cells from monocytes in vitro. Eur J Immunol 27: 431-441.
5. Chellaiah MA, Kizer N, Biswas R, Alvarez U, Strauss-Schoenberger J, Rifas L, Rittling SR, Denhardt DT, Hruska KA,. 2003. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14: 173-189.
6. da Costa CE, Annels NE, Faaij CM, Forsyth RG, Hogendoorn PC, Egeler RM,. 2005. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med 201: 687-693.
7. Del Prete A, Zaccagnino P, Di Paola M, Saltarella M, Oliveros Celis C, Nico B, Santoro G, Lorusso M,. 2008. Role of mitochondria and reactive oxygen species in dendritic cell differentiation and functions. Free Radic Biol Med 1: 1443-1451.
8. Denhardt DT, Lopez CA, Rollo EE, Hwang SM, An XR, Walther SE,. 1995. Osteopontin-induced modifications of cellular functions. Ann NY Acad Sci 760: 127-142.
9. Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D, Segawa T, Maeda M, Hamuro J, Nakayama T, Taniguchi M, Yagita H, Van Kaer L, Onõe K, Denhardt D, Rittling S, Uede T,. 2004. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21: 539-550.
10. Gao C, Guo H, Downey L, Marroquin C, Wei J, Kuo PC,. 2003. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 24: 1871-1878.
11. Gao YA, Agnihotri R, Vary CP, Liaw L,. 2004. Expression and characterization of recombinant osteopontin peptides representing matrix metalloproteinase proteolytic fragments. Matrix Biol 23: 457-466.
12. Green PM, Ludbrook SB, Miller DD, Horgan CM, Barry ST,. 2001. Structural elements of the osteopontin SVVYGLR motif important for the interaction with alpha(4) integrins. FEBS Lett 503: 75-79.
13. Hancock JT, Jones OT,. 1987. The inhibition by diphenyleneiodonium and its analogues of superoxide generation by macrophages. Biochem J 242: 103-107.
14. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW,. 1995. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 270: 26232-26238.
15. Lai CF, Seshadri V, Huang K, Shao JS, Cai J, Vattikuti R, Schumacher A, Loewy AP, Denhardt DT, Rittling SR, Towler DA,. 2006. An osteopontin-NADPH oxidase signaling cascade promotes pro-matrix metalloproteinase 9 activation in aortic mesenchymal cells. Circ Res 98: 1479-1489.
16. Lyle AN, Joseph G, Fan AE, Weiss D, Landázuri N, Taylor WR,. 2012. Reactive oxygen species regulate osteopontin expression in a murine model of postischemic neovascularization. Arterioscler Thromb Vasc Biol 32: 1383-1391.
17. Morimoto A, Shioda Y, Imamura T, Kanegane H, Sato T, Kudo K, Nakagawa S, Nakadate H, Tauchi H, Hama A, Yasui M, Nagatoshi Y, Kinoshita A, Miyaji R, Anan T, Yabe M, Kamizono J,. 2011. Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan. Pediatr Blood Cancer 56: 110-115.
18. Morimoto J, Kon S, Matsui Y, Uede T,. 2010. Osteopontin; as a target molecule for the treatment of inflammatory diseases. Curr Drug Targets 11: 494-505.
19. Murakami I, Morimoto A, Oka T, Kuwamoto S, Kato M, Horie Y, Hayashi K, Gogusev J, Jaubert F, Imashuku S, Al-Kadar LA, Takata K, Yoshino T,. 2013. IL-17A receptor expression differs between subclasses of Langerhans cell histiocytosis, which might settle the IL-17A controversy. Virchows Arch 462: 219-228.
20. Porter AG, Janicke RU,. 1999. Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104.
21. Prasse A, Stahl M, Schulz G, Kayser G, Wang L, Ask K, Yalcintepe J, Kirschbaum A, Bargagli E, Zissel G, Kolb M, Müller-Quernheim J, Weiss JM, Renkl AC,. 2009. Essential role of osteopontin in smoking-related interstitial lung diseases. Am J Pathol 174: 1683-1691.
22. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G,. 2002. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110: 1419-1427.
23. Rivollier A, Mazzorana M, Tebib J, Piperno M, Aitsiselmi T, Rabourdin-Combe C, Jurdic P, Servet-Delprat C,. 2004. Immature dendritic cell transdifferentiation into osteoclasts: A novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104: 4029-4037.
24. Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytela R, Giachelli CM,. 1996. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J Biol Chem 271: 28485-28491.
25. Standal T, Borset M, Sundan A,. 2004. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26: 179-184.
26. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA,. 1999. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 103: 47-54.
27. Teitelbaum SL,. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
28. Tuck AB, Chambers AF, Allan AL,. 2007. Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. J Cell Biochem 102: 859-868.
29. Uede T,. 2011. Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathol Int 61: 265-280.
30. Umekawa T, Tsuji H, Uemura H, Khan SR,. 2009. Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU Int 104: 115-120.
31. Yamaguchi Y, Shao Z, Sharif S, Du XY, Myles T, Merchant M, Harsh G, Glantz M, Recht L, Morser J, Leung LL,. 2013. Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. J Biol Chem 1: 3097-3111.
32. Yamamoto N, Nakashima T, Torikai M, Naruse T, Morimoto J, Kon S, Sakai F, Uede T,. 2007. Successful treatment of collagen-induced arthritis in non-human primates by chimeric anti-osteopontin antibody. Int Immunopharmacol 7: 1460-1470.
33. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y, Sheppard D,. 1999. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274: 36328-36334.
34. Yumoto K, Ishijima M, Rittling SR, Tsuji K, Tsuchiya Y, Kon S, Nifuji A, Uede T, Denhardt DT, Noda M,. 2002. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA 99: 4556-4561.